Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
External References
Posted by 
Last updated and reviewed on: October 17, 2025The following sources were used as references for this guide's content.
Cytokine Release Syndrome (CRS)
ICANS
Infection Prevention
- Prophylaxis - Pneumocystis jirovecii (carinii) pneumonia in cancer patients
- Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
- Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
- Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia
IVIG
Teclistamab
Elranatamab
Talquetamab
- Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
- U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
- Support & Resources | TALVEY® (talquetamab-tgvs)
- WHAT YOU SHOULD KNOW ABOUT TALVEY™
Linvoseltamab
Bispecifics in Clinical Trials
- Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
- Bispecific Antibodies in Earlier Lines of Therapy for Patients With Multiple Myeloma: A Bright Future for the New Kids on the Block